Abstract
Early diagnosis of Alzheimer`s disease (AD) is currently difficult and involves a complex approach including clinical assessment, neuroimaging, and measurement of amyloid-β (Aβ) and tau levels in cerebrospinal fluid (CSF). A better mechanistic understanding is needed to develop more accurate and even presymptomatic diagnostic tools. It has been shown that Aβ derived from amyloid-containing brain tissue has prion-like properties: it induces misfolding and aggregation of Aβ when injected into human amyloid precursor protein (APP) transgenic mice. In contrast, Aβ in the CSF has been less studied, and it is not clear whether it also exhibits prion-like characteristics, which might provide a sensitive diagnostic tool. Therefore, we collected CSF from APP transgenic mice carrying the Swedish mutation (APP23 mice), and injected it intracerebrally into young mice from the same transgenic line. We found that CSF derived Aβ did not induce increased β-amyloidosis, even after long incubation periods and additional concentration. This suggests that Aβ present in the CSF does not have the same prion-like properties as the Aβ species in the brain.
Keywords: Alzheimer's disease, amyloid-beta, Aβ, prion, cerebrospinal fluid, diagnostics, transgenic mouse models.
Current Alzheimer Research
Title:Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties
Volume: 12 Issue: 9
Author(s): Zhiva Skachokova, Frederik Sprenger, Karin Breu, Dorothee Abramowski, Florence Clavaguera, Jurgen Hench, Matthias Staufenbiel, Markus Tolnay and David T. Winkler
Affiliation:
Keywords: Alzheimer's disease, amyloid-beta, Aβ, prion, cerebrospinal fluid, diagnostics, transgenic mouse models.
Abstract: Early diagnosis of Alzheimer`s disease (AD) is currently difficult and involves a complex approach including clinical assessment, neuroimaging, and measurement of amyloid-β (Aβ) and tau levels in cerebrospinal fluid (CSF). A better mechanistic understanding is needed to develop more accurate and even presymptomatic diagnostic tools. It has been shown that Aβ derived from amyloid-containing brain tissue has prion-like properties: it induces misfolding and aggregation of Aβ when injected into human amyloid precursor protein (APP) transgenic mice. In contrast, Aβ in the CSF has been less studied, and it is not clear whether it also exhibits prion-like characteristics, which might provide a sensitive diagnostic tool. Therefore, we collected CSF from APP transgenic mice carrying the Swedish mutation (APP23 mice), and injected it intracerebrally into young mice from the same transgenic line. We found that CSF derived Aβ did not induce increased β-amyloidosis, even after long incubation periods and additional concentration. This suggests that Aβ present in the CSF does not have the same prion-like properties as the Aβ species in the brain.
Export Options
About this article
Cite this article as:
Skachokova Zhiva, Sprenger Frederik, Breu Karin, Abramowski Dorothee, Clavaguera Florence, Hench Jurgen, Staufenbiel Matthias, Tolnay Markus and Winkler T. David, Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710115022
DOI https://dx.doi.org/10.2174/1567205012666150710115022 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
Current Alzheimer Research Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research Role of Psychiatrists in the Diagnosis and Management of Alzheimer's Disease “Revisited”: A Review and Clinical Opinion
Current Psychiatry Reviews Lactoferrin Suppresses Decreased Locomotor Activities by Improving Dopamine and Serotonin Release in the Amygdala of Ovariectomized Rats
Current Molecular Pharmacology Novel Indole-Isoxazole Hybrids: Synthesis and In Vitro Anti-Cholinesterase Activity
Letters in Drug Design & Discovery Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design Cyclopropyl Scaffold: A Generalist for Marketed Drugs
Mini-Reviews in Medicinal Chemistry Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Defects in RNA Metabolism links FTD and ALS Pathogenesis: TDP-43, FUS, and C9orf72
Current Enzyme Inhibition Entrainment of the Human Circadian Clock to the Light-Dark Cycle and its Impact on Patients in the ICU and Nursing Home Settings
Current Pharmaceutical Design Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Hydrolytic Activity of Amyloid-beta and its Inhibition with Short Peptides
Current Medicinal Chemistry - Central Nervous System Agents